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To the Editor: In their ‘dark’ editorial, Drs Rovin and
Herbert came to the conclusion that for the initial choice of
hypertension management, instead of a diuretic ‘a drug
without an obvious dark side such as an angiotensin
converting enzyme inhibitor (ACEI)’ should be selected.1
We are somewhat puzzled by this recommendation because
just as diuretics and most other drug classes, angiotensin
converting enzyme (ACE) inhibitors have a distinctly dark
side that has been swept under the rug for many years—
angioedema is a rare but potentially fatal complication
of ACE inhibitor therapy. Admittedly, angioedema is rare,
occurring in less than 1 of 500 per year.2 About 20%
of all angioedemas are life threatening and among the life-
threatening ones about 16% are fatal, unless intubated.2
However, given that the worldwide exposure to ACE
inhibitors comprises more than 30 million patients, these
numbers still give us a conservative estimate of more than a
thousand episodes of potentially fatal angioedema per year.2
Indeed, in the HOPE study as well as in ALLHAT, a fatality
was reported with ACE inhibitor therapy. Dean et al.,3 in
2001, reported a total of six ACE inhibitor-treated patients all
of whom asphyxiated because of angioedema of the tongue,
oropharynx, or larynx. With one exception, all of these
patients had been on ACE inhibitors for months and years.
Of note, Dean et al. received these six cases in the Franklyn
County Coroner’s office between 1998 and 2000 in
Columbus, Ohio—ironically the very city from which the
editorial of Rovin and Hebert originates.
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We thank Drs Messerli, Phung, and Nussberger for
reminding the readers of Kidney International that no
medication is completely free of adverse side effects, and
that angiotensin-converting enzyme inhibitors (ACEi) are
no exception.1 They raise the issue of fatal angioedema
from ACEi therapy as an example of its dark side. While
this is certainly a potential complication of ACEi, it is a
dramatic event that is readily apparent, unlike the
insidious development of metabolic and perhaps renal
parenchymal complications of long-term thiazide therapy.
Angioedema from ACEi is exceedingly rare, seen in about
0.1% of patients2 and tends to occur soon after initiation of
therapy, although it can be significantly delayed.2,3 Messerli
and co-workers1,4 point out that 20% of ACEi angioedemas
are life threatening, and 16% of these may be fatal. A large,
population-based study of 1.2 million people given
enalapril found that 22% of angioedemas were life
threatening, but only one death was attributable to ACEi-
related angioedema.2 A study of the Tennessee Medicaid
database from 1986 to 1992 found no ACEi-related
angioedema deaths in 52 734 patient-years of ACEi
therapy.5 With regard to the ALLHAT angioedema death
cited by Messerli et al., this occurred when a patient was
re-challenged with an ACEi (personal communication
from Dr Jackson Wright, Case Western Reserve Univer-
sity), and thus was preventable. Furthermore, it is our
sense that the medical community is now well aware of this
potential problem with ACEi, and that ACEi will be
stopped before major difficulties arise. Such expectation
was not always the case. In the Tennessee Medicaid study
only 37% of patients with ACEi-related angioedema had
their condition correctly diagnosed at the time of their
initial presentation.
In summary, we suggest that ACEi has an outstanding
safety and efficacy record compared to other antihyper-
tensive agents, and the cardiovascular benefits are so
great6 that the very small risk of severe ACEi-related
angioedema should not determine whether ACEi therapy
is used.
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